Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000667905 | SCV000792429 | likely pathogenic | Retinitis pigmentosa 25 | 2017-06-22 | criteria provided, single submitter | clinical testing | |
Blueprint Genetics | RCV001073812 | SCV001239374 | likely pathogenic | Retinal dystrophy | 2018-04-18 | criteria provided, single submitter | clinical testing | |
Ocular Genomics Institute, |
RCV000667905 | SCV001573288 | pathogenic | Retinitis pigmentosa 25 | 2021-04-08 | criteria provided, single submitter | research | The EYS c.4393dup variant was identified in an individual with retinitis pigmentosa with a presumed recessive inheritance pattern. Through a review of available evidence we were able to apply the following criteria: PVS1, PM2, PP1. Based on this evidence we have classified this variant as Pathogenic. |
Labcorp Genetics |
RCV001868218 | SCV002216376 | pathogenic | not provided | 2024-07-30 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ala1465Glyfs*6) in the EYS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EYS are known to be pathogenic (PMID: 18836446, 20333770). This variant is present in population databases (rs750840208, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with EYS-related conditions. ClinVar contains an entry for this variant (Variation ID: 552610). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000667905 | SCV004192870 | likely pathogenic | Retinitis pigmentosa 25 | 2023-10-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000667905 | SCV005670607 | likely pathogenic | Retinitis pigmentosa 25 | 2024-04-11 | criteria provided, single submitter | clinical testing |